SCHEMBL21525977

SCHEMBL21525977

CCS(=O)(=O)c1cc(C(Br)=NOCC(F)(F)F)cnc1-c1nc2cc(S(=O)(=O)C(F)(F)F)ccc2o1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ UTRN P46939 3/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ AHR P35869 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ MAOB P27338 1/20 0.33
▸ SLC47A1 Q96FL8 1/20 0.33
▸ CETP P11597 1/20 0.33
▸ MAPT P10636 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ SMN1; SMN2 Q16637 3/20 0.32
▸ LMNA P02545 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ HSF1 Q00613 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21810394 1.00 UTRN (0.35) UTRNCYP1A2AHRHDAC6MAOB
SCHEMBL21810448 0.87 UTRN (0.33) UTRNCYP1A2AHRHDAC6MAOB
SCHEMBL21525979 0.87 UTRN (0.33) UTRNCYP1A2AHRHDAC6MAOB
SCHEMBL29603138 0.87 UTRN (0.33) UTRNCYP1A2AHRHDAC6MAOB
SCHEMBL21525980 0.87 CYP1A2 (0.30) UTRNCYP1A2AHRHDAC6
SCHEMBL21810435 0.87 CYP1A2 (0.30) UTRNCYP1A2AHRHDAC6
SCHEMBL21525982 0.83 CETP (0.37) UTRNCYP1A2AHRHDAC6MAOB
SCHEMBL21525988 0.83 UTRN (0.41) UTRNCYP1A2AHRHDAC6MAOB
SCHEMBL21525986 0.82 UTRN (0.39) UTRNCYP1A2AHRHDAC6MAOB
SCHEMBL25315137 0.80 UTRN (0.43) UTRNCYP1A2AHRHDAC6MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3564238-B1 FUSED HETEROCYCLIC COMPOUND HAVING OXIME GROUP OR SALTS THEREOF, AGRICULTURAL/HORTICULTURAL INSECTICIDE CONTAINING SAID COMPOUNDS, AND METHOD FOR USING SAID INSECTICIDE NIHON NOHYAKU CO LTD (JP) 2021-10-13 — — EP disclosed
US-10856548-B2 Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound or the salt, and method for using the insecticide NIHON NOHYAKU CO., LTD. (JP) 2020-12-08 — — US disclosed
US-20200085054-A1 OXIME GROUP-CONTAINING CONDENSED HETEROCYCLIC COMPOUND OR SALT THEREOF, AGRICULTURAL AND HORTICULTURAL INSECTICIDE COMPRISING THE COMPOUND OR THE SALT, AND METHOD FOR USING THE INSECTICIDE NIHON NOHYAKU CO., LTD. (JP) 2020-03-19 — — US disclosed
EP-3564238-A1 FUSED HETEROCYCLIC COMPOUND HAVING OXIME GROUP OR SALTS THEREOF, AGRICULTURAL/HORTICULTURAL INSECTICIDE CONTAINING SAID COMPOUNDS, AND METHOD FOR USING SAID INSECTICIDE Nihon Nohyaku Co., Ltd. (JP) 2019-11-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200085054-A1 OXIME GROUP-CONTAINING CONDENSED HETEROCYCLIC COMPOUND OR SALT THEREOF, AGRICULTURAL AND HORTICULTURAL INSECTICIDE COMPRISING THE COMPOUND OR THE SALT, AND METHOD FOR USING THE INSECTICIDE OXSR1, CBR3, OSR1 UTRN 4859/4885CYP1A2 186/4885AHR 956/4885
US-10856548-B2 Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound or the salt, and method for using the insecticide OXSR1, CBR3, OSR1 UTRN 4859/4885CYP1A2 186/4885AHR 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback